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Integrated genomic analysis of
mitochondrial RNA processing in human
cancers
Youssef Idaghdour1* and Alan Hodgkinson2*
Abstract
Background: The mitochondrial genome is transcribed as continuous polycistrons of RNA containing multiple genes.
As a consequence, post-transcriptional events are critical for the regulation of gene expression and therefore all aspects
of mitochondrial function. One particularly important process is the m1A/m1G RNA methylation of the ninth position of
different mitochondrial tRNAs, which allows efficient processing of mitochondrial mRNAs and protein translation, and
de-regulation of genes involved in these processes has been associated with altered mitochondrial function. Although
mitochondria play a key role in cancer, the status of mitochondrial RNA processing in tumorigenesis is unknown.
Methods: We measure and assess mitochondrial RNA processing using integrated genomic analysis of RNA sequencing
and genotyping data from 1226 samples across 12 different cancer types. We focus on the levels of m1A and m1G RNA
methylation in mitochondrial tRNAs in normal and tumor samples and use supervised and unsupervised statistical
analysis to compare the levels of these modifications to patient whole genome genotypes, nuclear gene expression,
and survival outcomes.
Results: We find significant changes to m1A and m1G RNA methylation levels in mitochondrial tRNAs in tumor tissues
across all cancers. Pathways of RNA processing are strongly associated with methylation levels in normal tissues (P = 3.
27 × 10−31), yet these associations are lost in tumors. Furthermore, we report 18 gene-by-disease-state interactions
where altered RNA methylation levels occur under cancer status conditional on genotype, implicating genes associated
with mitochondrial function or cancer (e.g., CACNA2D2, LMO2, and FLT3) and suggesting that nuclear genetic variation can
potentially modulate an individual’s ability to maintain unaltered rates of mitochondrial RNA processing under
cancer status. Finally, we report a significant association between the magnitude of methylation level changes in
tumors and patient survival outcomes.
Conclusions: We report widespread variation of mitochondrial RNA processing between normal and tumor tissues
across all cancer types investigated and show that these alterations are likely modulated by patient genotype and may
impact patient survival outcomes. These results highlight the potential clinical relevance of altered mitochondrial RNA
processing and provide broad new insights into the importance and complexity of these events in cancer.
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Background
The role of mitochondria in cancer has long been
controversial. Although mitochondria are essential
for tumor cell growth [1–3], many lines of evidence
indicate that altered mitochondrial bioenergetics are
required for tumor initiation and persistence. First,
the up-regulation of anaerobic energy production via
glycolysis, the so-called Warburg effect, is well documented
and recognized as a hallmark of cancer [4, 5]. Second,
mutations in nuclear-encoded mitochondrial genes have
been identified in patients with cancer, with links to the
disease well established in some cases [6]. Third, increased
numbers of mutations are consistently found in the
mitochondrial genomes of tumor cells compared to
normal samples [7–9]. These mutations may merely tag
carcinogenesis, but whether other genetic properties of
mitochondrial genomes are important in tumorigenesis
remains one of the important unanswered questions in
cancer biology.
In line with this, recent studies have looked beyond
mitochondrial DNA mutations to consider other important
genetic processes. Mitochondrial copy number has been
found to vary between paired normal and tumor samples
[10, 11], mitochondrial biogenesis is often altered in cancer
cells [6, 10], and recent work has suggested that mitochon-
drial RNA transcripts may accumulate differently in cancer
tissues [12]. The idea that post-transcriptional processing of
the mitochondrial transcriptome may be altered in cancer
is intriguing. Mitochondrial RNA is transcribed as con-
tinuous polycistrons, which are then processed under
the “punctuation model”, whereby tRNAs that intersperse
mRNAs are targeted for modification and cleavage by nu-
clear-encoded proteins [13–16]. The polycistronic na-
ture of mitochondrial transcription means that post-
transcriptional events are particularly important: knock-
down of RNA processing enzymes influences mitochondrial
mRNA and protein levels, and mitochondrial function [17]
and the level of m1A and m1G post-transcriptional methy-
lation at the ninth position of mitochondrial tRNAs (p9
sites) can potentially influence downstream metabolic
phenotypes [18]. Indeed, p9 site methylation is thought
to influence the correct folding of mitochondrial tRNAs,
thus affecting the rate of cleavage within the polycistronic
transcript and potentially impacting upon their down-
stream roles in protein translation [19–21].
There are several reasons to believe that altered process-
ing of mitochondrial RNA (which we now use to denote all
processing events that occur after transcription of the
mitochondrial polycistronic strand, including nucleotide
modifications, base additions, and strand cleavage events)
may be involved in cancer. For example, mutations within
the mitochondrial processing enzyme RNase Z were found
to be segregating with prostate cancer incidence in human
pedigrees [22], and mutations within mitochondrial tRNAs,
which are heavily post-transcriptionally modified, have been
previously linked with cancer [23]. Here, we assess whether
mitochondrial RNA processing is altered in cancer by
analyzing RNA sequencing data from 1226 paired normal
and tumor samples across 12 cancer types from The
Cancer Genome Atlas (TCGA). We find significant and
consistent signatures of increased mitochondrial tRNA
p9 site methylation in tumor tissues compared to paired
adjacent normal samples that appears to be coupled with
major deregulation of nuclear RNA processing genes. Fur-
thermore, we find evidence of context-specific SNPs that
are associated with methylation levels in tumor but not
normal samples (genotype-by-disease-state interactions),
and we observe a significant relationship between the
magnitude of change in mitochondrial tRNA p9 site
methylation in tumor tissues and the survival outcome
of patients with kidney renal clear cell carcinoma, thus




Raw sequencing files (fastq format) were obtained from
TCGA through the CGHub repository via dbGaP accession
number phs000178.v9.p8 [24, 25] for 12 cancer types where
at least 25 paired tumor and adjacent normal samples were
available (we do not use matched blood normal samples).
These included breast invasive carcinoma (BRCA), colon
adenocarcinoma (COAD), head and neck squamous cell
carcinoma (HNSC), kidney chromophobe (KICH), kidney
renal clear cell carcinoma (KIRC), kidney renal papillary cell
carcinoma (KIRP), liver hepatocellular carcinoma (LIHC),
lung adenocarcinoma (LUAD), lung squamous cell
carcinoma (LUSC), prostate adenocarcinoma (PRAD),
stomach adenocarcinoma (STAD), and thyroid carcinoma
(THCA). In total, we obtained 1226 RNA sequencing
datasets for analysis.
Sequencing reads were trimmed for adaptor sequences,
terminal bases with quality lower than 20, and poly(A) tails
of five nucleotides or greater before being aligned to a refer-
ence genome (1000G GRCh37 reference, which contains
the mitochondrial rCRS NC_012920.1) with STAR 2.51a
[26], using default parameters, two-pass mapping, and ver-
sion 19 of the Gencode gene annotation. Careful attention
was paid to minimize the likelihood of incorrectly placed
reads, particularly those associated with NUMT sequences.
To achieve this, a stringent filtering pipeline was applied, as
we previously demonstrated [18], focusing only on properly
paired and uniquely mapped reads.
Gene expression levels
To calculate transcript abundances, we used HTseq [27]
with default parameters, the “intersection-nonempty”
model, and Gencode gene annotation file v19. Raw counts
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were then converted to transcripts per million (TPM).
Within the TPM calculation, for mitochondrial genes the
total number of fragments mapping to the mitochondrial
transcriptome was used to normalize for library size. Since
the total amount of mitochondrial RNA in each sample is
influenced by both mitochondrial copy number and poly-
cistronic transcription rate, normalizing the data in this
way controls for these two factors and allows us to focus
on variation in gene expression driven by processing of
the polycistronic strand. For nuclear genes, the total
library size was used. TPM scores were then log10-
transformed and median normalized. Principal component
analysis and distribution analysis were used to identify
outlier samples. Samples greater than three standard
deviations from the mean in any of the first three principal
components were deemed outliers. All samples paired with
these outliers were also removed from subsequent analysis,
resulting in a set of 1196 samples across all cancers. Distri-
bution analysis shows that samples within each cancer type
had similar distributions, suggesting that variations in the
data due to technical reasons are minimal.
Methylation levels at tRNA p9 sites
Previous studies have highlighted that sequencing mis-
matches observed in RNA sequencing data at particular
positions in the mitochondrial genome represent post-
transcriptional modification events [17, 18, 28]. The
assumption behind this approach is that chemical modifi-
cations of RNA either act as a road-block to the reverse
transcription enzyme during library preparation or cause
the enzyme to mis-incorporate nucleotides, resulting in
sequencing errors [29]. Recent work by Mercer et al. [28],
Sanchez et al. [17], and ourselves [18] has shown that
sequence mismatches occur at a high rate at the ninth
position of different mitochondrial tRNAs, which are posi-
tions that are known to be post-transcriptionally methyl-
ated, and subsequent experiments by ourselves [18] have
shown that the proportion of mismatches at these sites is
systematic and repeatable across replication experiments.
Recently, new sequencing methods have confirmed the
presence of post-transcriptional methylation events at 19/
22 p9 sites by comparing RNA sequencing data from
samples that have been treated with demethylation en-
zymes against matched untreated samples [30]. Within
this work, the general quantitative nature of using
mismatch and strand termination events as a proxy for
post-transcriptional modification was also shown, and
although the ratio of these events does not perfectly
match post-transcriptional modification levels (since
the reference allele is sometimes incorporated), the two
levels are highly similar. Under this model, we inferred
the level of p9 site methylation as the proportion of non-
reference alleles for the 11 positions identified as undergo-
ing post-transcriptional methylation in our previous study
[18] (positions 585, 1610, 4271, 5520, 7526, 8303, 9999,
10413, 12174, 12246, and 14734 in the mitochondrial
genome) using samtools v1.2 mpileup [31] with default
parameters to generate allele count files. It is important
to note that these p9 positions in the mitochondrial
genome have previously been shown not to overlap
with known variants in NUMT sequences in the human
reference using a careful and stringent mapping and
filtering strategy [18].
Within each cancer type (12 in total), we compare
methylation levels between normal and tumor samples
for each of the 11 p9 sites separately using Wilcoxon
signed rank tests, using only those sites where both tumor
and paired normal samples had at least 20× coverage.
Across all samples, the average coverage at p9 sites is
~600×. As an example, inferred methylation levels for the
11 p9 sites for KIRC are shown in Additional file 1: Figure
S1. In order to control for any biases in coverage, we re-
peated the analysis after resampling sequencing reads
within each individual and at each site to the lowest cover-
age found at that site in either the normal or tumor sam-
ple. To directly compare the levels of p9 methylation
across cancers, we standardized rates at each p9 site
within each cancer by dividing the proportion of mis-
matches by the maximum value observed across normal
and tumor samples at each site. This normalization en-
sures that methylation levels are on the same scale across
sites and cancers, yet variation is maintained across sam-
ples. To compare the levels of p9 methylation with cleav-
age rates at the 5′ end of mitochondrial tRNAs, we
calculated the proportion of reads that started or ended ei-
ther side of the position 9 bp upstream of the p9 site com-
pared to all reads covering that position. We considered
only sites with at least 20 individuals with 20× coverage at
both cleavage and p9 positions and used Spearman rank
correlation tests. For comparisons to mitochondrial gene
expression, we performed Spearman rank correlation
tests for each p9 site and within each cancer for normal
and tumor samples separately.
To ensure that confounding factors are not influencing
our results, we tested whether a number of features were
associated with p9 site methylation levels. In general,
since paired normal and tumor samples originate from
the same individual, many phenotypes will be identical
between sample pairs. However, to ensure that age and
sex are not affecting the results, we tested whether these
factors are correlated with methylation levels within
either normal or tumor samples for individuals that we
had genotyping data for; in all cases we find no signifi-
cant relationships (P > 0.05 after Bonferroni correction).
To test the impact of varying tumor purity on our
results we obtained measures of tumor purity and histo-
logical estimates of stromal cells and infiltrating lympho-
cytes from Yoshihara et al. [32] and compared these
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measures to changes in p9 site methylation levels be-
tween matched normal and tumor samples within each
cancer type using Spearman rank correlations. In total,
only one comparison out of 132 (11 p9 sites in 12 differ-
ent cancers) was significant after Bonferroni correction
(site 7526, stromal infiltrate in individuals with PRAD,
P = 0.00013), suggesting that tumor purity is not driv-
ing the observed changes in tumor samples.
Differential expression and cross-correlations with nuclear
gene expression
We evaluated the magnitude and significance of differ-
ential expression of transcripts of nuclear-encoded mito-
chondrial RNA-binding proteins [33] using analysis of
variance and Bonferroni thresholds to infer statistical
significance. In total, 99 transcripts out of 107 listed in
Wolf and Mootha [33] were deemed expressed in BRCA
and KIRC datasets (100 transcripts in THCA). Two-way
clustering of gene expression data of the full set of genes
encoding mitochondrial RNA-binding proteins was
generated using Ward’s method in JMP Genomics 8.0
(SAS Institute). To investigate the relationships between
nuclear gene expression traits and p9 site methylation
level, we performed an unbiased genome-wide association
between methylation level at 11 p9 sites and 16,736
expression traits in the BRCA dataset. We calculated
Spearman correlation across all individuals in each sample
type. The significance of correlations was assessed by cor-
recting for multiple testing, resulting in a Bonferroni
threshold of 3 × 10−6. In the main text we present results
for BRCA; however, we see the same general trends for
THCA and KIRC as significant associations in normal
tissue are altered in tumor samples (Additional file 1:
Figure S2). Gene set enrichment analysis was performed
using the Core Analysis Workflow implemented in the
Ingenuity Pathway Analysis package to measure the
likelihood that the association between nuclear genes
whose expression was significantly associated with p9
site methylation level and a given process or pathway is
due to random chance. The P value is calculated using
the right-tailed Fisher exact test that takes into consider-
ation the number of focus genes that participate in the
process in question and the total number of genes that are
known to be associated with that process in the human
reference set. The same analysis parameters were used for
BRCA, KIRC, and THCA (Additional file 1: Table S1).
Statistical interaction effects
Where available, we downloaded birdseed genotype files
generated from Affymetrix Genome-wide Human SNP
arrays (6.0) for all individuals for which we had RNA
sequencing data. Samples that did not pass TCGA quality
control were not used and, in total, data were available for
569 individuals. For each cancer type, we filtered out
genotypes with birdseed quality scores below 0.1 and kept
SNPs in Hardy–Weinberg equilibrium (P > 0.001). Since
sample sizes within cancers were generally small, we
converted minor homozygote alleles to heterozygotes
(dominant model). SNPs with minor allele frequency
(MAF) <5% were removed and we then ran a quantita-
tive trait model (GxE) in plink 1.07 [34], using the
levels of p9 methylation at sites where paired normal
and tumor samples had at least 20× coverage. Within
these tests, the levels of p9 site methylation were used
as the quantitative trait and sample type (normal or
tumor) as the environment, and regression coefficients
were compared between normal and tumor association
tests to generate a P value for the interaction term. In
order to ensure robust findings, we considered only
sites that had data for at least 40 individuals. QQ plots
for p9 sites and cancers showing significant interaction
effects are shown in Additional file 1: Figure S3. After
identifying SNPs that passed genome-wide significance,
we visually inspected data plots and made sure that the
uncovered associations are not driven by outliers. SNP
annotations were taken from the Affymetrix annotation
file associated with the array.
Survival analysis
We obtained patient survival data from TCGA and
performed survival analysis in R using the package
“Survival”. We limited analysis to cancers for which
we had RNA sequencing data for at least 50 individuals,
with a death rate of 25% (KIRC and LUAD). Censoring
was limited to 60 months, since most events happen dur-
ing this time. Cox proportional hazards tests were used to
model survival as a function of changes in p9 site methyla-
tion levels in tumor versus normal samples. For significant
associations, we tested Schoenfeld residuals to ensure that
the proportional hazards assumption was being met (P >
0.05 in all cases). To calculate meaningful hazard ratios,
the tests were repeated after binning changes in the levels
of p9 site methylation into two equal sized groups.
Results
Post-transcriptional changes in tumor cells
To study the patterns of mitochondrial RNA processing
in human cancers we mapped and filtered raw RNA
sequencing data from 1226 samples from matched tumor–
normal pairs across 12 cancer types from TCGA (Fig. 1a).
Using these data we inferred the level of m1A and m1G
post-transcriptional methylation occurring at 11 function-
ally important positions within mitochondrial tRNAs (the
ninth position of 11 different tRNAs, as identified in [18],
henceforth referred to as p9 sites) by using the proportion
of mismatches observed at these positions (referred to as
“p9 site methylation levels” throughout; see “Methods”), in
line with approaches taken by previous studies [17, 18, 28].
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For each of the 11 p9 sites and within each of the 12
cancers, we then compared the level of p9 site methylation
observed between paired normal and tumor samples
(11 × 12 = 132 comparisons in total).
In total, 50/132 comparisons show significant differences
between normal and tumor tissues at a 5% significance level
(Wilcoxon signed-rank tests) and 42 of these comparisons
show increases in the observed levels of p9 site methylation
in cancer tissue (Fig. 1b for examples showing all 11 p9
sites in KIRC; Additional file 1: Table S2). After applying
Bonferroni correction (within each cancer type, P < 0.0045),
23 comparisons remain significant, 22 of which show
increases of the levels of p9 site methylation in cancer tis-
sues. Resampling sequencing reads to the same depth in
paired normal and tumor samples (thus accounting for po-
tential biases in sequencing coverage) gives very similar re-
sults (Additional file 1: Table S3; see “Methods”). These
observations strongly suggest a widespread increase in the
level of p9 site methylation of mitochondrial tRNAs in
tumor tissue in multiple cancer types.
Next, we investigated whether the observed differences
in the levels of p9 site methylation are a general trend in
cancer. For each p9 site, we standardized the data within
each cancer type (thus maintaining cancer-associated
Fig. 1 Methylation differences between paired tumor and normal samples at tRNA p9 sites within mitochondrial tRNAs. a Number of normal–tumor
pairs for each cancer type, including breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), head and neck squamous cell carcinoma
(HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma
(LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), stomach adenocarcinoma (STAD) and
thyroid carcinoma (THCA). b Observed methylation levels for all 11 p9 sites within KIRC, split into normal and tumor. A similar plot showing all data
points is shown in Additional file 1: Figure S1. c Standardized methylation levels split into normal and tumor for all cancers combined for p9 sites 1610,
5520, and 7526. d Two-way hierarchical clustering of mean standardized methylation levels of all 11 p9 sites for both normal and tumor samples across
all cancer types
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patterns in methylation levels) and tested differences
between tumor and normal pairs across all cancer types
combined. In total, five out of the 11 p9 sites show
highly significant differences (P < 0.0045; Additional
file 1: Table S4; Fig. 1c for p9 sites 1610, 5520, and
7526). Following this, we averaged the level of p9 site
methylation by group and found that, strikingly, two-way
hierarchical clustering using all p9 site data from 24 cancer
sample-type sets revealed how groups cluster largely by
sample type (normal or tumor) with the exception of BRCA
tumor, COAD normal, and PRAD normal not clustering
within their respective sample type (Fig. 1d). These results
suggest that altered processing of mitochondrial RNA is a
consistent trend across multiple cancer types.
To infer the impact of changes at sites and cancers
where we observe significant differences (at P < 0.05), we
compared the levels of p9 site methylation across both
normal and tumor samples combined with the levels of
cleavage occurring at the 5′ end of each respective tRNA,
which we measured as the proportion of sequencing reads
starting or ending either side of this position. As a control,
we considered the level of cleavage at a further 9 bp up-
stream from each p9 site. Methylation levels significantly
correlate with cleavage rates for 9/43 comparisons after
Bonferroni correction (P < 0.001, versus one significant cor-
relation for the control) and for 16/43 comparisons at a 5%
significance level, with all significant correlations being in
the positive direction (Additional file 1: Table S5). Next, for
the same sites we tested whether p9 site methylation levels
are associated with tRNA expression levels across nor-
mal and cancer samples combined. To calculate tRNA
expression, we first normalized the coverage at each
site by dividing by the total number of reads mapping
to the mitochondria (following the approach of Stew-
art et al. [12]), and then averaged the rate across each
respective tRNA. In total, at 24/50 p9 sites the level of
methylation is correlated with tRNA expression levels
(P < 0.05, seven positive and 17 negative; Additional
file 1: Table S6). Finally, we considered the influence
of changes in p9 site methylation in cancer on mito-
chondrial coding gene expression: considering normal
samples separately, the levels of p9 methylation significantly
correlate with mitochondrial gene expression in 25 compar-
isons across cancer types (Additional file 2: Table S7;
Spearman rank P < 0.05 after Bonferroni correction
within cancer type, mostly negatively correlated with
MTCO3, MTCO2, and MTCO1 abundance and posi-
tively correlated with MTND2 abundance), yet in
tumor samples these relationships break down and
only two pairwise comparisons are significant. In all,
these analyses point to a link between p9 site methyla-
tion levels and other RNA processing events taking
place after transcription of the mitochondrial polycis-
tronic transcript.
Nuclear transcriptional signatures associated with
changes in mitochondrial RNA processing
Mitochondrial RNA transcription and processing, like
many other molecular processes taking place in mito-
chondria, is under strong nuclear control. As such, we
tested the hypothesis that the expression of nuclear-
encoded genes involved in mitochondrial RNA pro-
cessing is altered in tumors by performing differential
expression analysis. Raw RNA sequencing data were
aligned, filtered, and normalized as detailed in the
“Methods” and expression data for 99 mitochondrial
RNA-binding proteins (as listed in [33]) were retrieved
and compared between normal and tumor samples. In
this section we report results for BRCA only, since
this is the cancer type for which we have the most
paired samples (>100) and thus the most power; however,
we also see the same broad trends in other cancer types
with the next largest sample sizes (see “Methods”). In
total, we detected 55 genes differentially expressed at
Bonferroni significance (Fig. 2a) and the heatmap of
all 99 gene expression traits surveyed shows that sam-
ples cluster largely by sample type (normal or tumor;
Additional file 1: Figure S4).
Following this, we tested for associations between the
expression levels of the 99 nuclear-encoded factors and
the levels of p9 site methylation. We performed cross-
correlation analysis (Spearman rank) across all individuals
for all possible 1089 p9 site methylation level–nuclear
gene expression trait pairs in normal and tumor samples
separately. The test revealed significant associations for
eight of the 11 p9 sites in normal samples and the total
cumulative number of Bonferroni-significant associations
was 369 across all eight p9 sites (P < 0.0005; Fig. 2b for
distributions of coefficients; variance explained ranges
between −0.64 and 0.47). In sharp contrast, no significant
associations were detected in tumor samples (Fig. 2b), in-
dicating major deregulation of these processes in cancer.
A two-way hierarchical clustering heatmap of the full
correlation matrix (Additional file 1: Figure S5) shows the
consistency of the associations across different p9 sites in
normal samples, whereas these associations are highly
perturbed under cancer status.
Next, we identified cell-wide processes associated with
mitochondrial RNA processing by performing global
cross-correlation analysis between the expression levels
of all nuclear genes and the levels of methylation at each
p9 position using the same strategy as outlined above
and using a Bonferroni corrected P value threshold of
3 × 10−6 (0.05/16,736). In normal samples, the test re-
vealed an average of 2311 significant associations for
eight of the 11 p9 sites (Fig. 2c; Additional file 1: Table S8;
three sites show no significant associations; variance ex-
plained ranges between −0.66 and 0.62). To investigate
the functional characteristics of nuclear genes whose
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expression levels are associated with the levels of methyla-
tion at the p9 site showing the strongest signal in normal
cells (p9 site 10413 and 6061 genes) we used Ingenuity
Pathway Analysis. We find that “RNA post-transcriptional
modification” is the top and most highly enriched molecu-
lar and cellular function category with five significantly
enriched sub-functions (P value range 2.77 × 10−6 to
3.27 × 10−31; Fig. 2d; “Processing of RNA” was the most
enriched sub-function), supporting the idea that many nu-
clear genes play a role in mitochondrial RNA processing.
We also observe similar results for other cancer types and
at other p9 sites (see “Methods”). However, we again find
striking differences in tumor samples, where we detect only
two significant associations across all p9 sites, pointing
to major deregulation of nuclear-associated mitochondrial
RNA processing in cancer (Additional file 1: Figure S6).
Fig. 2 Differential expression and correlations between the levels of tRNA p9 methylation and nuclear gene expression in BRCA. a Volcano plot
of statistical significance (shown as the negative logarithm of the P value on the y-axis) versus magnitude of differential gene expression (shown
as the log base 2 of magnitude of mean expression difference on the x-axis) of 99 genes encoding mtRNA-binding proteins. The dashed line indicates
Bonferroni statistical significance. b Distribution of Spearman correlations between gene expression levels of the 99 genes and the levels of methylation at
p9 site 10413. Associations that are significant at Bonferroni threshold in normal samples are highlighted with the dark green color. c Two-way clustering of
Spearman correlations of expression levels of 16,736 genes (columns) and methylation level at 11 p9 sites (rows) in the BRCA dataset. Correlation values are
visualized using a red-to-gray-to-blue color theme (values range from 0.62 to −0.66). d Ingenuity pathway enrichment analysis of nuclear genes whose
expression levels are associated with the levels of methylation at p9 site 10413 in the BRCA dataset. The top four categories are shown and the P value
represents the most significant biological sub-function within each category
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Joint action of genotype and cancer state on post-
transcriptional methylation
Given the general increase in the levels of p9 methylation
in cancers, we assessed whether nuclear genetic variants
could modulate the observed changes in mitochondrial
RNA processing differentially in tumor relative to normal
samples. To do this, we looked for genotype-by-disease-
state (tumor or normal) interaction effects on p9 site
methylation levels across cancer types. We obtained geno-
typing data for the same samples for which we measured
the levels of p9 site methylation and limited the analysis
to SNPs in Hardy–Weinberg equilibrium (P > 0.001),
those where at least 40 individuals had methylation
data available and with at least five individuals carrying
a minor allele. Under a dominant model and after filter-
ing SNPs for MAF >5%, this analysis identified 18 peak
genotype-by-disease-state interactions at genome-wide
significance across cancer types and p9 sites (Table 1;
Fig. 3 showing examples). In 15 cases the minor allele
is associated with increased levels of p9 site methylation
in tumor but not normal samples, suggesting that mito-
chondrial RNA processing is affected differently in indi-
viduals carrying these alleles under cancer status.
After initial discovery, we attempted to replicate each
genome-wide significant interaction effect in other cancer
types at any p9 site (P < 0.001, under the same criteria out-
lined above). In doing so, we found an interaction effect
for rs317391 in KIRC at p9 site 12146 (P = 2.16 × 10−5;
interaction effect originally observed in BRCA at p9 site
7526, P = 2.46 × 10−9). This SNP falls within an intron of
the gene ASIC2, which is part of a sodium channel super-
family. We also found that rs341737 is an interaction SNP
for the levels of methylation at p9 site 14734 in PRAD
(P = 0.000745; interaction effect originally observed in
LUAD at p9 site 14734, P = 9.86 × 10−9). This SNP falls
in an intergenic region near to CMSD1, a known tumor
suppressor gene. The fact that these SNPs are also associ-
ated with similar effects in other cancer types suggests
that our initial observations are robust.
Potential clinical implications
In order to relate changes in mitochondrial RNA process-
ing to potential clinical outcomes we used Cox proportional
hazards tests to determine if changes in the levels of p9 site
methylation between paired normal and tumor samples
are a significant predictor of patient survival outcomes.
Table 1 Interaction effects on tRNA p9 site methylation
Cancer p9 Site rs number Chr Position Location Gene N MAF MAF range P value
BRCA 7526 rs3781574 11 33885268 intron LMO2 46 0.161 0.128–0.231 4.61E-11
BRCA 7526 rs17690328 11 33885390 intron LMO2 46 0.135 0.016–0.190 1.17E-08
BRCA 7526 rs317391 17 32174605 intron ASIC2 44 0.085 0.014–0.485 2.46E-09
KIRC 1610 rs258701 7 81761122 intron CACNA2D1 61 0.058 0.072–0.167 8.27E-10
KIRC 8303 rs10266772 7 14132727 Intergenic - 61 0.080 0.079–0.254 2.27E-08
KIRC 10413 rs1028014 8 40698232 intron ZMAT4 64 0.174 0.085–0.236 2.88E-08
KIRC 12146 rs17164416 5 99387447 Intergenic - 65 0.051 0.000–0.188 9.95E-09
LIHC 12146 rs41465346 1 219059708 Intergenic - 48 0.052 0.006–0.304 3.73E-08
LIHC 12146 rs16926871 8 62027498 intron CLVS1 47 0.074 0.038–0.270 1.24E-08
LUAD 585 rs13029285 2 205916078 intron PARD3B 49 0.057 0.003–0.076 1.81E-10
LUAD 10413 rs7328699 13 28615701 intron FLT3 46 0.107 0.000–0.124 9.15E-10
LUAD 10413 rs12591927 15 31833911 intron OTUD7A 44 0.077 0.016–0.289 2.44E-08
LUAD 10413 rs17003208 22 43073031 Intergenic - 45 0.074 0.096–0.431 1.13E-08
LUAD 10413 rs17003212 22 43079754 Intergenic - 46 0.063 0.096–0.434 1.18E-11
LUAD 12146 rs4741498 9 15424938 intron SNAPC3 45 0.063 0.005–0.256 3.68E-08
LUAD 12146 rs7026970 9 15445219 intron SNAPC3 45 0.063 0.040–0.355 3.68E-08
LUAD 12146 rs7046713 9 15458921 intron SNAPC3 45 0.063 0.031–0.357 3.68E-08
LUAD 14734 rs341737 8 2782370 Intergenic - 54 0.107 0.081–0.225 9.86E-09
PRAD 10413 rs7631369 3 1028679 Intergenic - 48 0.070 0.015–0.418 3.45E-08
PRAD 10413 rs7301597 12 30175147 Intergenic - 48 0.050 0.000–0.105 3.85E-09
THCA 585 rs17033484 4 156686737 intron GUCY1B3 54 0.089 0.058–0.187 3.78E-08
THCA 4271 rs2145836 20 47421064 intron PREX1 44 0.054 0.000–0.058 4.41E-08
MAF denotes minor allele frequency of the polymorphism in TCGA data for the specific cancer type, and MAF range denotes the range of minor allele frequencies
across continents observed in 1000 Genomes phase 3 data [41]
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To ensure power to detect significant associations, we
focused on cancers where we had data for at least 50
individuals with >25% death rate within 60 months of
diagnosis (only KIRC and LUAD meet this criterion).
Treating p9 methylation differences as a quantitative
trait we find that methylation differences do not signifi-
cantly predict patient survival in LUAD. For KIRC, how-
ever, seven p9 sites are significant predictors of patient
survival at the 5% level, two of which remain significant
after Bonferroni correction (Additional file 1: Table S9),
with larger increases in the levels of p9 site methylation in
tumor compared to paired normal samples being associ-
ated with worse survival. The strongest effect occurs for
p9 site 10413 (ninth position of TRNR; P = 0.000476).
Repeating the analysis including age, sex, and ethnicity
gives similar results: five out of seven remain significant at
P < 0.05, one out of two remain significant after Bonferroni
correction, and the strongest effect for the ninth position of
TRNR has a P value of 0.00151. Treating the change in the
levels of methylation at this site as a categorical variable
with data binned into two equal sized groups of high and
low methylation differences (Fig. 4; P = 0.036), the model
suggests that those in the larger methylation differences
group are 2.784 (95% confidence interval (1.07,7.25)) times
more likely to die over a 60-month period after diagnosis.
Discussion
By analyzing RNA sequencing data across a large number
of individuals and sample types, we find significant and
consistent changes in the levels of m1A and m1G post-
transcriptional methylation at functionally important
positions within mitochondrial tRNAs in tumor samples
compared to paired normal samples. These changes ap-
pear to be a widespread phenomenon across different
types of tumors and suggest that altered mitochondrial
RNA processing is a hallmark of cancer. We hypothesize
that oncogenic signals trigger these changes, which in turn
promote energetic plasticity in tumor cells in a manner
Fig. 3 Interaction effects on tRNA p9 site methylation. The three plots show examples of SNPs that have different relationships with the levels of
p9 methylation in normal (blue) and tumor (red) samples
Fig. 4 Survival analysis. Data show relationship between the magnitude of change of the levels of methylation between paired tumor and normal
samples at p9 site 10413 and survival rates for patients with KIRC
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that is not dependent on hard-coded mitochondrial
genetic changes. The observed positive correlation between
p9 site methylation levels and tRNA 5′ cleavage rates high-
lights the link between the two processes during and/or
after transcription of the mitochondrial polycistronic
transcript and suggests that methylation is coupled with
cleavage. Our analysis also shows that, across different
cancers and p9 sites, methylation levels are associated
with tRNA/coding gene expression in both positive and
negative directions. This suggests that the downstream
impacts of changes to p9 site methylation levels on
mitochondrial gene expression are complex and may
vary both along the polycistronic strand and in different
cancer types.
A large number of associations between p9 site methyla-
tion levels and the expression of nuclear genes are highly
significant in normal tissue, yet these relationships com-
pletely break down in tumors. Since associations in normal
tissues contain a highly statistically significant enrichment
of RNA post-transcriptional modification genes, it is pos-
sible that a subset of these genes directly or indirectly affect
the levels of p9 site methylation. However, given the large
number of observed associations, they also potentially
encompass genes whose change in expression is a down-
stream response to changes in p9 site methylation. Analysis
of genes most strongly associated with p9 methylation rates
in normal tissues would be a good starting point to tease
apart these processes. Mitochondrial tRNAs are key for the
translation of genes of the oxidative phosphorylation system
[16], and given the connection between cell growth and
protein synthesis, it stands to reason that increased rates of
tRNA processing would augment the translational and
metabolic capacity of mitochondria, modulate the cell cycle,
and, ultimately, promote uncontrolled growth. Further
studies are warranted to illuminate the molecular mecha-
nisms likely coupling altered levels of mitochondrial RNA
processing to cell growth and other tumorigenesis steps
such as cell invasion and migration.
The observed differences in the levels of p9 methylation
between normal and tumor samples are significant; how-
ever, a subset of tumor samples exhibit methylation levels
in the range detected in normal samples. The levels of p9
site methylation for these samples are highly predictable
from allelic variation, and as such we hypothesize that
nuclear genetic variation can modulate an individual’s
ability to maintain normal levels of mitochondrial RNA
processing during cancer development and subsequently
influence patient survival outcomes. Our tests to uncover
genotype-by-disease-state interactions revealed 18 peak
variants at genome-wide significance and these in vivo
interaction effects serve as a promising starting point for a
potential method to uncover biomarkers for predictable
responses to cancer progression. Although no single inter-
action should be taken as strong evidence of a role for a
given haplotype in tumor development, among the
genome-wide significant interaction SNPs that fall
within intronic or exonic regions (11 in total) there
are several noteworthy examples where these genes
may be interesting for further study. Four genes have a
link to mitochondrial function, cellular proliferation,
or apoptosis (CACNA2D2, CLVS1, OTUD7A, and FLT3),
three genes have been linked to neurological function (and
amyotrophic lateral sclerosis in particular), where dys-
functional mitochondria have a known role [35, 36]
(ASIC2, CLVS1, PARD3B) and four genes have been
previously linked with cancer (LMO2, CACNA2D2, FLT3,
and PREX1). These associations were detected through
careful statistical analysis and filtering; however, only
future functional work would help uncover the mecha-
nisms through which causal variants tagged by these asso-
ciation might modulate p9 site methylation. We note that
the MAF range of the 18 SNPs is 0.054–0.174 in TCGA
data for the relevant cancer type, but the frequency of
these markers vary more wildly across 1000 genome con-
tinental groupings (Table 1), suggesting that there may be
population differences in the ability to modulate p9 site
methylation under cancer status.
Finally, we find that altered mitochondrial tRNA
methylation profiles in cancer samples correlate with
patient survival outcomes, suggesting that these processes
have important downstream consequences and may be
clinically relevant. An alternative hypothesis is that other
confounding factors strongly linked to survival may influ-
ence mitochondrial RNA processing; further analysis with
larger sample sizes is required to truly understand these
relationships.
Conclusions
Our study demonstrates that there are major changes to
mitochondrial RNA processing in cancers that occur
strongly and consistently across different cancer types.
We hypothesize that tumor cells use these processes to
regulate their mitochondrial output and consequently
also the shift between different ways of producing energy
and biomaterials in a manner that is not dependent on
hard-coded genetic changes. Also, altered mitochondrial
RNA processing appears to be due to a breakdown in
the pathways involved in RNA modification and process-
ing and may be modulated at least in part by common
genetic variation. We also link the extent of changes in
mitochondrial processing with patient survival outcomes,
thus making a strong case for the prognosis potential of
these events in cancer.
Taken as a whole, these results provide strong evidence
for altered mitochondrial post-transcriptional modification
and processing taking place in cancer and complement
an emerging appreciation for the roles that post-
transcriptional and post-translational regulation play
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in the etiology of cancers [37–40]. Although the mecha-
nisms underlying these alterations remain to be resolved,
it is tempting to speculate that restoring normal levels of
modification and processing of mitochondrial RNA would
represent a promising area of investigation for the devel-
opment of new anticancer therapeutic interventions.
Additional files
Additional file 1: Figures S1–6 and Tables S1–9. (PDF 1792 kb)
Additional file 2: Table S7. Comparisons between methylation levels
at each p9 site with mitochondrial gene expression. Analyses were performed
within either normal or tumor samples, and across all cancers. (XLSX 148 kb)
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